1.70
0.11 (6.92%)
0.11 (6.92%)
Upgrade to Real-Time
Premarket
| Volume | 169,626 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Rigel Pharmaceuticals Inc | RIGL | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.11 | 6.92% | 1.70 | 07:09:23 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.59 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 585 | 169,626 | - | 0.64 - 4.24 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 07:09:23 | formt | 500 | $ 1.70 | USD |
Period:
Draw Mode:
Rigel Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 314.56M | 172.84M | 147.36M | $ 149.24M | $ -137.40M | -0.12 | -3.10 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 1.37M | 1.50% |
Rigel Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RIGL Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.47 | 1.67 | 1.38 | 1.52 | 3,375,022 | 0.23 | 15.65% |
| 1 Month | 1.29 | 1.67 | 1.11 | 1.39 | 3,592,229 | 0.41 | 31.78% |
| 3 Months | 1.89 | 1.92 | 0.64 | 1.05 | 7,057,112 | -0.19 | -10.05% |
| 6 Months | 2.46 | 3.515 | 0.64 | 1.47 | 4,303,094 | -0.76 | -30.89% |
| 1 Year | 3.62 | 4.24 | 0.64 | 1.87 | 2,862,636 | -1.92 | -53.04% |
| 3 Years | 1.95 | 5.50 | 0.64 | 2.75 | 2,871,830 | -0.25 | -12.82% |
| 5 Years | 2.18 | 5.50 | 0.64 | 2.86 | 2,499,955 | -0.48 | -22.02% |
Rigel Pharmaceuticals Description
| Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor. |